Elacestrant Dihydrochloride Patent Expiration
Elacestrant Dihydrochloride is Used for the treatment of ER-positive breast cancer, especially in patients who have already undergone at least one line of endocrine therapy. It was first introduced by Stemline Therapeutics Inc
Elacestrant Dihydrochloride Patents
Given below is the list of patents protecting Elacestrant Dihydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Orserdu | US10385008 | Polymorphic forms of RAD1901-2HCL | Jan 05, 2038 | Stemline Therap |
| Orserdu | US10745343 | Polymorphic forms of RAD1901-2HCl | Jan 05, 2038 | Stemline Therap |
| Orserdu | US11819480 | Methods for treating cancer | Nov 29, 2036 | Stemline Therap |
| Orserdu | US10071066 | Method of treating cancer using selective estrogen receptor modulators | Oct 10, 2034 | Stemline Therap |
| Orserdu | US10420734 | Method of treating cancer using selective estrogen receptor modulators | Oct 10, 2034 | Stemline Therap |
| Orserdu | US11779552 | Method of treating cancer using selective estrogen receptor modulators | Oct 10, 2034 | Stemline Therap |
| Orserdu | US7612114 | Selective estrogen receptor modulator | Aug 18, 2026 | Stemline Therap |
| Orserdu | US8399520 | Selective estrogen receptor modulator | Dec 25, 2024 | Stemline Therap |
Elacestrant Dihydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List